Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Phase 1/?2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Complete Title: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway
Trial Phase: I/II
Investigator: Gabriela Chiorean
This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS, MAPK pathways.
Keywords:
- Solid Tumors
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Colorectal Neoplasms
- Advanced Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Gabriela Chiorean
RG1123375
NCT05578092
A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway
Solid Tumors
Lung Carcinoma, Non-Small-Cell (NSCLC)
Colorectal Neoplasms
Advanced Solid Tumors